Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Solid Biosciences Inc. - Common Stock (NQ:SLDB)

5.470 +0.210 (+3.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Solid Biosciences Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Solid Biosciences: Q1 Earnings Insights
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Solid Biosciences Touts Encouraging Preclinical Data From Potential Duchenne Gene Therapy
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
From Kahn Swick & Foti, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
7 Sizzling Stocks That Are Oblivious to the Manic Market
While some stocks to buy have performed surprisingly well recently, they remain relatively obscure, providing a contrarian opportunity. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
Upgrades 
Via Benzinga
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
From Kahn Swick & Foti, LLC
Via Business Wire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Ainos (NASDAQ:AIMD) shares increased by 46.4% to $2.02 during Friday's pre-market session. The market value of their outstanding shares is at $39.3 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million. 
Via Benzinga
Solid Biosciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Solid Biosciences (NASDAQ:SLDB) posted sales of $6.17 million. Earnings were up 0.93%, but Solid Biosciences still reported an overall loss of $25.09... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
What 4 Analyst Ratings Have To Say About Solid Biosciences
Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.